All In Biotech

NDA 208684 · Ptc Therap

Emflaza

Deflazacort · Oral · Corticosteroid

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Feb 9, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

19

8 Phase 3, 0 recruiting

FAERS reports

6,421

3,256 serious, 311 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2026.

EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older ( 1 )

Mechanism: Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 7, 2019 Supplement 3 · Efficacy · priority review OrphanLabelLetter
  • Feb 9, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
4 products under this application
  • EMFLAZA · DEFLAZACORT 30MG · TABLET, ORAL · Prescription · TE AB
  • EMFLAZA · DEFLAZACORT 6MG · TABLET, ORAL · Prescription · TE AB
  • EMFLAZA · DEFLAZACORT 36MG · TABLET, ORAL · Prescription · TE AB
  • EMFLAZA · DEFLAZACORT 18MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Deflazacort" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • weight increased532
  • off label use423
  • fall302
  • vomiting262
  • product dose omission issue260
  • no adverse event257
  • pyrexia232
  • pain231
  • drug ineffective220
  • headache220
  • malaise216
  • influenza209

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200426
200530
200636
200732
200850
200954
201065
201170
2012110
2013124
2014116
2015140
2016125
2017423
20181,227
20191,635
2020312
2021386
2022252
2023331
2024348
2025330
2026199

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Emflaza (Deflazacort)

2024 spending

$15.4M

Beneficiaries

113

1,084 claims

Per beneficiary

$136,433

$435.98 per unit

View as table
YearSpending
2020$5,876,991
2021$7,596,448
2022$11,065,608
2023$15,369,330
2024$15,416,876

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 123 on PubMed

Sponsor: Ptc Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.